CN104619710B - 用于治疗再灌注损伤的氧杂二环庚烷和氧杂二环庚烯 - Google Patents

用于治疗再灌注损伤的氧杂二环庚烷和氧杂二环庚烯 Download PDF

Info

Publication number
CN104619710B
CN104619710B CN201380035527.1A CN201380035527A CN104619710B CN 104619710 B CN104619710 B CN 104619710B CN 201380035527 A CN201380035527 A CN 201380035527A CN 104619710 B CN104619710 B CN 104619710B
Authority
CN
China
Prior art keywords
alkyl
alkenyl
alkynyl
independently
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201380035527.1A
Other languages
English (en)
Chinese (zh)
Other versions
CN104619710A (zh
Inventor
约翰·S·科瓦奇
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lixte Biotechnology Inc
Original Assignee
Lixte Biotechnology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lixte Biotechnology Inc filed Critical Lixte Biotechnology Inc
Publication of CN104619710A publication Critical patent/CN104619710A/zh
Application granted granted Critical
Publication of CN104619710B publication Critical patent/CN104619710B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Surgery (AREA)
  • Dermatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201380035527.1A 2012-06-29 2013-06-28 用于治疗再灌注损伤的氧杂二环庚烷和氧杂二环庚烯 Expired - Fee Related CN104619710B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261666535P 2012-06-29 2012-06-29
US61/666,535 2012-06-29
US201361782894P 2013-03-14 2013-03-14
US61/782,894 2013-03-14
PCT/US2013/048697 WO2014005080A1 (en) 2012-06-29 2013-06-28 Oxabicycloheptanes and oxabicycloheptenes for the treatment of reperfusion injury

Publications (2)

Publication Number Publication Date
CN104619710A CN104619710A (zh) 2015-05-13
CN104619710B true CN104619710B (zh) 2017-09-22

Family

ID=49783920

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380035527.1A Expired - Fee Related CN104619710B (zh) 2012-06-29 2013-06-28 用于治疗再灌注损伤的氧杂二环庚烷和氧杂二环庚烯

Country Status (6)

Country Link
US (1) US20150174123A1 (https=)
EP (1) EP2870161B1 (https=)
JP (2) JP6262225B2 (https=)
CN (1) CN104619710B (https=)
CA (1) CA2876703A1 (https=)
WO (1) WO2014005080A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010147612A1 (en) 2009-06-18 2010-12-23 Lixte Biotechnology, Inc. Methods of modulating cell regulation by inhibiting p53
US10531655B2 (en) 2011-12-02 2020-01-14 The Regents Of The University Of California Reperfusion protection solution and uses thereof
EP2867239A4 (en) 2012-06-29 2015-12-23 Lixte Biotechnology Inc OXABICYCLOHEPTANES AND OXABICYCLOHEPTENES FOR THE TREATMENT OF DIABETES
KR20160004299A (ko) 2013-04-09 2016-01-12 릭스트 바이오테크놀로지, 인코포레이티드 옥사바이시클로헵탄류 및 옥사바이시클로헵텐류의 제형
EP3143026B1 (en) 2014-05-13 2024-07-10 Novartis AG Compounds and compositions for inducing chondrogenesis
EP3171870B1 (en) * 2014-07-24 2021-10-20 H. Lee Moffitt Cancer Center And Research Institute, Inc. Protein phosphatase 2a inhibitors for treating myelodysplastic syndromes
WO2016040877A1 (en) * 2014-09-12 2016-03-17 Lixte Biotechnology, Inc. Human dosing of phosphatase inhibitor
CA2977256C (en) 2015-02-19 2023-08-08 John S. Kovach Oxabicycloheptanes and oxabicycloheptenes for the treatment of depressive and stress disorders
ES2985668T3 (es) 2015-05-15 2024-11-06 Lixte Biotechnology Inc Profármacos de oxabicicloheptano para uso en el tratamiento del cáncer
EP4324477A3 (en) 2016-12-08 2024-05-22 Lixte Biotechnology, Inc. Oxabicycloheptanes for modulation of immune response
WO2019185708A1 (en) 2018-03-28 2019-10-03 Georg-August-Universitaet Goettingen, Stiftung Oeffentlichen Rechts, Universitaetsmedizin Prevention or treatment of chronic organ injury
CN118791500B (zh) * 2024-06-17 2025-11-21 中国药科大学 7-氧杂双环[2.2.1]庚烷-2,3-二羧酸类衍生物及其制备方法和应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5914242A (en) * 1996-10-04 1999-06-22 South Alabama Medical Science Foundation Method for diminishing myocardial infarction using protein phosphatase inhibitors
US20100029683A1 (en) * 2008-08-01 2010-02-04 Kovach John S Methods for regulating cell mitosis by inhibiting serine/threonine phosphateses

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4931460A (en) * 1987-09-17 1990-06-05 E. R. Squibb & Sons, Inc. Post-ischemic myocardial dysfunction using thromboxane A2 antagonists
BRPI0806365B8 (pt) 2007-02-06 2021-05-25 Lixte Biotechnology Holdings Inc composto, uso do composto, composição farmacêutica e uso da composição farmacêutica
WO2010014220A1 (en) 2008-08-01 2010-02-04 Lixte Biotechnology, Inc. Neuroprotective agents for the prevention and treatment of neurodegenerative diseases
KR20160004299A (ko) * 2013-04-09 2016-01-12 릭스트 바이오테크놀로지, 인코포레이티드 옥사바이시클로헵탄류 및 옥사바이시클로헵텐류의 제형
WO2016040877A1 (en) * 2014-09-12 2016-03-17 Lixte Biotechnology, Inc. Human dosing of phosphatase inhibitor

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5914242A (en) * 1996-10-04 1999-06-22 South Alabama Medical Science Foundation Method for diminishing myocardial infarction using protein phosphatase inhibitors
US20100029683A1 (en) * 2008-08-01 2010-02-04 Kovach John S Methods for regulating cell mitosis by inhibiting serine/threonine phosphateses

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Ascorbate protects against vascular leakage in cecal ligation and puncture-induced septic peritonitis;Gang Zhou等;《American Journal of Physiology-Regulatory，Intergrative and Comparative Physiology》;20111123;第302卷;第R409-R416页 *
PP2A 的结构和功能新进展;顾燕云等;《国外医学分子生物学分册》;20031231;第25卷(第41期);228-231 *

Also Published As

Publication number Publication date
WO2014005080A1 (en) 2014-01-03
EP2870161A4 (en) 2015-12-23
HK1209424A1 (en) 2016-04-01
JP6262225B2 (ja) 2018-01-17
JP2015522032A (ja) 2015-08-03
EP2870161B1 (en) 2018-08-08
CA2876703A1 (en) 2014-01-03
US20150174123A1 (en) 2015-06-25
EP2870161A1 (en) 2015-05-13
JP2018048178A (ja) 2018-03-29
CN104619710A (zh) 2015-05-13

Similar Documents

Publication Publication Date Title
CN104619710B (zh) 用于治疗再灌注损伤的氧杂二环庚烷和氧杂二环庚烯
US10668062B2 (en) Oxabicycloheptanes and oxabicycloheptenes for the treatment of diabetes
US7132430B2 (en) Treatment of cardiovascular and related pathologies
US20220184075A1 (en) Pharmaceutical composition containing hdac6 inhibitor as active ingredient for prevention or treatment of itching
EP0682947A1 (en) Medicament for therapeutic and prophylactic treatment of diseases caused by smooth muscle cell hyperplasia
CA3170031A1 (en) Nicotinamide mononucleotide derivatives for the treatment of arrhythmia
WO2010034269A1 (zh) 2,5-二羟基甲基-3,6-二甲基吡嗪及其衍生物在制药中的应用
JP2018537522A (ja) 組合せ
AU2022394648B2 (en) An Anti-hypoxic/anoxic Injury Use of a Magnolol and/or Honokiol Aromatic Ring Amino-substituted Derivative and a Pharmaceutical Composition
HK1209424B (en) Oxabicycloheptanes and oxabicycloheptenes for the treatment of reperfusion injury
WO1995002407A1 (en) Neuron protective and novel orotic ester
US20250099455A1 (en) Treatment for congestive heart failure
KR100508623B1 (ko) 마크롤라이드 화합물의 신규한 용도
JP2000026295A (ja) 虚血再潅流損傷の治療薬ならび不整脈および心筋梗塞による心不全を含む細胞機能障害の治療薬
JPH08508710A (ja) 新規処置方法
CN118524839A (zh) 充血性心力衰竭的治疗
JPH04342526A (ja) 四肢の末梢循環改善剤及び血管攣縮抑制剤
KR0156985B1 (ko) 신규 2-클로로-3-치환아미노-1,4-나프탈렌디온 유도체
JP2001064183A (ja) 虚血・再灌流傷害抑制剤
JPWO2002028392A1 (ja) 脳循環障害治療剤

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20170922